HPRA Drug Safety Newsletter Edition 109
Download:
hpra-drug-safety-newsletter-edition-109.pdf
257 KB
The latest edition of the HPRA Drug Safety Newsletter (DSN) includes important updates to support the safe and appropriate use of the following medicines:
- Nurofen Plus (codeine/ibuprofen) - serious clinical harms, including renal tubular acidosis and severe hypokalaemia, following prolonged use of codeine/ibuprofen at higher than recommended doses
- Leuprorelin-containing depot medicines - risk of idiopathic intracranial hypertension (pseudotumor cerebri)
- Pholcodine-containing medicines - review of risk of developing anaphylactic reactions to neuromuscular blocking agents (NMBA)
- Product information updates recommended by the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) for clopidogrel and pegfilgrastim
« Back